Alternative names (4)
interventionModel • interventionType • keyInterventions • mainInterventionRandom triples
| Subject | Object |
|---|---|
| gptkb:EPI-B | Bepirovirsen |
| gptkb:NCT01396499 | gptkb:RO5185426 |
| gptkb:NCT01327846 | gptkb:RO5185426 |
| gptkb:Diabetes_Prevention_Program_(DPP)_clinical_trial | lifestyle modification |
| gptkb:NCT02142738 | gptkb:Nivolumab |
| gptkb:Malaria_Consortium_SMC | preventive treatment |
| gptkb:NCT03775200 | gptkb:Placebo |
| gptkb:NCT03581786 | 5-Fluorouracil |
| gptkb:Moving_to_Opportunity_research | housing vouchers |
| gptkb:NCT05020678 | gptkb:Molnupiravir |
| gptkb:NCT03400917 | gptkb:Pembrolizumab |
| gptkb:NCT02915432 | 5-Fluorouracil |
| gptkb:MRC_Streptomycin_Trial | streptomycin |
| gptkb:CLARITY-AD | gptkb:lecanemab |
| gptkb:A_Study_of_Pembrolizumab_(MK-3475)_in_Combination_With_Axitinib_as_First-Line_Treatment_for_Locally_Advanced_or_Metastatic_Renal_Cell_Carcinoma_(MK-3475-426/KEYNOTE-426) | gptkb:Pembrolizumab |
| gptkb:NCT03581786 | gptkb:Cisplatin |
| gptkb:NCT02366143 | Chemotherapy |
| gptkb:Diabetes_Prevention_Program | gptkb:metformin |
| gptkb:NCT04601051 | gptkb:Placebo |
| gptkb:FELIX_study | genetically modified T-cells |